{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:44:42Z","timestamp":1789037082212,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd004197.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000}}],"reference-count":343,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004197.pub6","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T10:21:03Z","timestamp":1685701263000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Simon C","family":"Langton Hewer","sequence":"additional","affiliation":[{"name":"Paediatric Respiratory Medicine; Bristol Royal Hospital for Children; Bristol UK"},{"name":"Population Health Sciences; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherie","family":"Smith","sequence":"additional","affiliation":[{"name":"Academic Unit of Lifespan and Population Health, School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J","family":"Rowbotham","sequence":"additional","affiliation":[{"name":"Academic Unit of Lifespan and Population Health, School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Yule","sequence":"additional","affiliation":[{"name":"Academic Unit of Lifespan and Population Health, School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R","family":"Smyth","sequence":"additional","affiliation":[{"name":"Academic Unit of Lifespan and Population Health, School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"10.1002\/14651858.CD004197.pub6-BIB0001|cit1","unstructured":"Study of aztreonam for inhalation in children with cystic fibrosis and new infection of the airways by pseudomonas aeruginosa bacteria www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-002749-42-GR"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0002|cit2","unstructured":"Study of aztreonam for inhalation in children with cystic fibrosis and new Infection of the airways by pseudomonas aeruginosa bacteria (ALPINE 2) clinicaltrials.gov\/ct2\/show\/NCT03219164"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0003|cit3","unstructured":"Evaluation of the efficacy and safety of tobramycin for the treatment of early infections of P. aeruginosa in cystic fibrosis subjects aged from 3 months to less than 7 years trialsearch.who.int\/?TrialID=EUCTR2009-016590-15-IT"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0004|cit4","unstructured":"Randomized, controlled study of CF patients between 3 months and less than 7 years clinicaltrials.gov\/show\/NCT01082367"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0005|cit5","first-page":"S1","article-title":"TOBI\u00ae for eradication of early P. aeruginosa infection in paediatric cystic fibrosis patients: the EARLY study","volume":"15 Suppl 1","author":"Ratjen","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2018.04.002","article-title":"Eradication of early P. aeruginosa infection in children <7years of age with cystic fibrosis: the early study","volume":"18","author":"Ratjen","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0007|cit7","first-page":"300","article-title":"A randomized, controlled trial of inhaled tobramycin in young children with cystic fibrosis: eradication of pseudomonas from the lower airway","volume":"Suppl 24","author":"Gibson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"841 Online Supp","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0010|cit10","first-page":"262","article-title":"Serum pharmacokinetics and safety of inhaled tobramycin in very young CF patients","volume":"Suppl 19","author":"Rosenfeld","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0011|cit11","first-page":"106","article-title":"Serum and lower respiratory tract tobramycin concentrations produced by inhaled tobramycin (TOBI) in young children with cystic fibrosis","volume":"Suppl 19","author":"Rosenfeld","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.jcf.2020.11.005","article-title":"Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis","volume":"20","author":"Magaret","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial","volume":"198","author":"Mayer-Hamblett","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1164\/rccm.v199erratum2","article-title":"Erratum: azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial","volume":"199","author":"Mayer-Hamblett","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0015|cit15","unstructured":"Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis clinicaltrials.gov\/show\/NCT02054156"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0016|cit16","unstructured":"Pittman JE Skalland MS Sagel SD Ramsey BW Mayer-Hamblett N Retsch-Bogart GZ Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas Journal of Cystic Fibrosis 10.1016\/j.jcf.2022.02.015"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0017|cit17","first-page":"380","article-title":"Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial","volume":"52 Suppl 47","author":"Ramsey","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0018|cit18","unstructured":"Comparison of 2 treatment regimens for eradication of p aeruginosa infection in children with cystic fibrosis clinicaltrials.gov\/show\/NCT01400750"},{"issue":"S2","key":"10.1002\/14651858.CD004197.pub6-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1569-1993(08)60246-5","article-title":"Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin\/ciprofloxacin","volume":"7","author":"Proesmans","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub6-BIB0020|cit20","first-page":"321","article-title":"Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin\/ciprofloxacin","volume":"44","author":"Proesmans","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(11)60119-7","article-title":"Eradication of recent pseudomonas aeruginosa infection: TOBI versus Colistineb\u00ae\/ ciprofloxacin","volume":"10 Suppl 1","author":"Proesmans","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2012.06.001","article-title":"Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"12","author":"Proesmans","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0023|cit23","unstructured":"ELITE study: the microbiological efficacy and safety of two treatment regimens of inhaled tobramycine nebuliser solution (TNS) for the treatment of early onset pseudomonas aeruginosa lower respiratory tract infection in subjects with cystic fibrosis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN80955954"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0024|cit24","unstructured":"Efficacy and safety of 28 or 56 day treatment for pseudomonas aeruginosa in children with cystic fibrosis (ELITE) clinicaltrials.gov\/show\/NCT00391976"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0025|cit25","unstructured":"ELITE study www.who.int\/trialsearch\/Trial2.aspx?TrialID=NTR377"},{"issue":"S29","key":"10.1002\/14651858.CD004197.pub6-BIB0026|cit26","first-page":"318","article-title":"Inhaled tobramycin nebuliser solution for treatment of early Pseudomonas aeruginosa infection: first results from the Elite study","volume":"41","author":"Ratjen","year":"2006","journal-title":"Pediatric Pulmonlogy"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(06)80085-8","article-title":"Safety of inhaled tobramycin nebuliser solution for treatment of early pseudomonas aeruginosa infection: first results from the ELITE study","volume":"5 Suppl 1","author":"Ratjen","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"issue":"S31","key":"10.1002\/14651858.CD004197.pub6-BIB0029|cit29","first-page":"319","article-title":"Short and long-term efficacy of inhaled tobramycin in early P. Aeruginosa infection: the ELITE study","volume":"43","author":"Ratjen","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60098-3","article-title":"Inhaled tobramycin nebulizer solution for treatment of early Pseudomonas aeruginosa infection; the ELITE study","volume":"7 Suppl 2","author":"Ratjen","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0031|cit31","first-page":"348","article-title":"Semi-automated rep-pcr genotyping of pseudomonas aeruginosa in Italian CF patients in eradication therapy","volume":"45 Suppl 33","author":"Cariani","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0032|cit32","first-page":"288","article-title":"Anti-P.aeruginosa antibodies and microbiological outcome in patients treated with early eradication therapy","volume":"48 Suppl 36","author":"Dolce","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0033|cit33","unstructured":"Early antibiotic treatment in pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomised policentric study on two different protocols - #FFC17\/2007 https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2008-006502-42-IT"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub6-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/thoraxjnl-2011-200832","article-title":"Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols","volume":"67","author":"Taccetti","year":"2012","journal-title":"Thorax"},{"issue":"S33","key":"10.1002\/14651858.CD004197.pub6-BIB0035|cit35","first-page":"337","article-title":"Pseudomonas aeruginosa eradication in cystic fibrosis: preliminary data from a randomized multicenter study of two different early antibiotic treatment protocols","volume":"45","author":"Taccetti","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"S34","key":"10.1002\/14651858.CD004197.pub6-BIB0036|cit36","first-page":"317","article-title":"Pseudomonas aeruginosa microbiological status and emergence of other pathogens after early eradication treatment in cystic fibrosis: a post-trial follow-up","volume":"46","author":"Taccetti","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub6-BIB0037|cit37","first-page":"354","article-title":"Early antibiotic treatment for Pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomized multicenter study of two different protocols","volume":"44","author":"Taccetti","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"S34","key":"10.1002\/14651858.CD004197.pub6-BIB0038|cit38","first-page":"317","article-title":"Pseudomonas aeruginosa eradication in cystic fibrosis: final results of a randomized multicenter study of two different early antibiotic treatment protocols","volume":"46","author":"Taccetti","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0039|cit39","first-page":"328","article-title":"Is early eradication treatment against P.aeruginosa associated with the emergence of other non-fermenter gram negatives","volume":"48 Suppl 36","author":"Taccetti","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0040|cit40","first-page":"5","article-title":"Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing classic treatment protocols with classic treatment together with antibiotic treatment of upper airways","volume":"14 Suppl 1","author":"Taccetti","year":"2019","journal-title":"Multidisciplinary Respiratory Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(10)60111-7","article-title":"Epidemiology of first\/new Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"9 Suppl 1","author":"Zavataro","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004197.pub6-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(19)30118-3","article-title":"Comparative genomics study of a set of Pseudomonas aeruginosa isolates from the TORPEDO-CF trial","volume":"18","author":"Cazares","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0043|cit43","unstructured":"Trial of optimal therapy for pseudomonas eradication in cystic fibrosis - TORPEDO-CF https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-012575-10-SE"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0044|cit44","unstructured":"Trial of optimal therapy for pseudomonas eradication in cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN02734162"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1569-1993(17)30428-9","article-title":"TORPEDO-CF-completion of recruitment to trial of optimal regimen for eradication of new infection with Pseudomonas aeruginosa","volume":"16 Suppl 1","author":"Langton Hewer","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0046|cit46","first-page":"294","article-title":"Torpedo-CF \u2013 trial of optimal therapy for pseudomonas eradication in cystic fibrosis","volume":"53 Suppl 2","author":"Langton Hewer","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"65","key":"10.1002\/14651858.CD004197.pub6-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25650","article-title":"Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT","volume":"25","author":"Langton Hewer","year":"2021","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub6-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial","volume":"8","author":"Langton Hewer","year":"2020","journal-title":"Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(19)30117-1","article-title":"Effectiveness of IV compared to oral eradication therapy of Pseudomonas aeruginosa in cystic fibrosis: multicentre randomised controlled trial (TORPEDO-CF)","volume":"18 Suppl 1","author":"Langton Hewer","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD004197.pub6-BIB0050|cit50","first-page":"302","article-title":"Intravenous vs oral antibiotics for eradication of pseudomonas aeruginosa in cystic fibrosis (Torpedo-CF): a randomised controlled trial","volume":"54","author":"Smyth","year":"2019","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0051|cit51","unstructured":"TORPEDO-CF www.isrctn.com\/ISRCTN02734162"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0052|cit52","unstructured":"University of Liverpool Clinical Trials Research Centre TORPEDO-CF 2019 www.liverpool.ac.uk\/systems-molecular-and-integrative-biology\/research\/groups\/ctrc\/portfolio\/"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcf.2012.08.001","article-title":"Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial","volume":"12","author":"Anstead","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S34","key":"10.1002\/14651858.CD004197.pub6-BIB0054|cit54","first-page":"303","article-title":"Pseudomonas aeruginosa serology predicts response to treatment and re-infection in the EPIC clinical study","volume":"46","author":"Anstead","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcf.2013.07.006","article-title":"Pulmonary exacerbations in CF patients with early lung disease","volume":"13","author":"Anstead","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciab208","article-title":"Association of intensity of antipseudomonal antibiotic therapy with risk of treatment-emergent organisms in children with cystic fibrosis and newly acquired Pseudomonas aeruginosa","volume":"73","author":"Cogen","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub6-BIB0057|cit57","first-page":"183","article-title":"Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study","volume":"44","author":"Hamblett","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0058|cit58","first-page":"317","article-title":"Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis","volume":"49","author":"Hamblett","year":"2014","journal-title":"Pediatric Pulmonology"},{"issue":"S35","key":"10.1002\/14651858.CD004197.pub6-BIB0059|cit59","first-page":"317","article-title":"Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial","volume":"47","author":"Hoffman","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0060|cit60","first-page":"349","article-title":"Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients","volume":"49","author":"Jorth","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0061|cit61","first-page":"304","article-title":"Early evolution of pseudomonas aeruginosa during cystic fibrosis infection [abstract]","volume":"50 Suppl 41","author":"Jorth","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"S33","key":"10.1002\/14651858.CD004197.pub6-BIB0062|cit62","first-page":"335","article-title":"Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants & prior antibiotic exposure","volume":"45","author":"Khan","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/cid\/civ377","article-title":"Impact of sustained eradication of new pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis","volume":"61","author":"Mayer-Hamblett","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ppul.21525","article-title":"Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis","volume":"47","author":"Mayer-Hamblett","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub6-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ppul.22693","article-title":"Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis","volume":"48","author":"Mayer-Hamblett","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0066|cit66","unstructured":"Comparison of two treatment regimens to reduce PA infection in children with cystic fibrosis clinicaltrials.gov\/show\/NCT00097773"},{"issue":"S28","key":"10.1002\/14651858.CD004197.pub6-BIB0067|cit67","first-page":"146","article-title":"TOBI use in infants and children with early Pseudomonas Aeruginosa infection - duration of effect and epic update","volume":"40","author":"Ramsey","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1569-1993(10)60210-X","article-title":"Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"9 Suppl 1","author":"Treggiari","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub6-BIB0069|cit69","first-page":"316","article-title":"Early anti-pseudomonal infection in children with CF: study population and conduct of the \"EPIC\" clinical trial","volume":"44","author":"Treggiari","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Archives of Pediatrics and Adolescent Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","article-title":"Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study","volume":"30","author":"Treggiari","year":"2009","journal-title":"Contempory Clinical Trials"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1164\/rccm.201410-1877LE","article-title":"Air contamination with bacteria in cystic fibrosis clinics: implications for prevention strategies","volume":"191","author":"Zuckerman","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8769","key":"10.1002\/14651858.CD004197.pub6-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment","volume":"338","author":"Valerius","year":"1991","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004197.pub6-BIB0074|cit74","first-page":"248","article-title":"Prevention of chronic colonization with Pseudomonas aeruginosa in patients with CF by early treatment with ciprofloxacin and colistin aerosol inhalations","volume":"9","author":"Valerius","year":"1990","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0075|cit75","first-page":"250","article-title":"Prevention of chronic pseudomonas aeruginosa infection by early inhalation therapy with tobramycin","volume":"Suppl 10","author":"Ratjen","year":"1994","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J","article-title":"Placebo-controlled, double-blind, randomised study of aerosolised tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis","volume":"25","author":"Wiesemann","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1378\/chest.122.3.930","article-title":"Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin","volume":"122","author":"Alothman","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0078|cit78","first-page":"298","article-title":"In cystic fibrosis (CF) patients, does the inhalation of an intravenous tobramycin preparation result in more bronchospasm than a preservative free tobramycin preparation?","volume":"Suppl 20","author":"Alothman","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1378\/chest.127.2.522","article-title":"Bronchial constriction and inhaled colistin in cystic fibrosis","volume":"127","author":"Alothman","year":"2005","journal-title":"Chest"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/thx.53.9.732","article-title":"Long term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"53","author":"Ballman","year":"1998","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/adc.67.9.1086","article-title":"The value of serum IgG titres against Pseudomonas aeruginosa in the management of early infection in cystic fibrosis","volume":"67","author":"Brett","year":"1992","journal-title":"Archives of Disease in Childhood"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0082|cit82","first-page":"307","article-title":"Impact of eradication of Pseudomonas aeruginosa on survival in Mexican patients with cystic fibrosis","volume":"66","author":"Bustamante","year":"2014","journal-title":"Revista de Investigacion Clinica"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006454-199701000-00031","article-title":"Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime\/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group","volume":"16","author":"Church","year":"1997","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0086|cit86","first-page":"299","article-title":"Full analysis of data from two phase II blinded & placebo-controlled studies of nebulized liposomal amikacin for inhalation (Arikace) in the treatment of CF patients with pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Clancy","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60099-5","article-title":"A randomised placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"7 Suppl 2","author":"Dupont","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD004197.pub6-BIB0088|cit88","first-page":"A1836","article-title":"Evaluation of two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin (arikace\") in the treatment of cystic fibrosis patients with pseudomonas aeruginosa lung infection","volume":"181","author":"Dupont","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0089|cit89","first-page":"301","article-title":"A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas Aeruginosa lung infection","volume":"43 Suppl 31","author":"Dupont","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A1199","article-title":"A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection (protocol TR02-105)","volume":"179","author":"Gupta","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ppul.21376","article-title":"Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis","volume":"46","author":"Coates","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S1569-1993(09)60261-7","article-title":"Lung delivery of a new tobramycin nebuliser solution (150mg\/1.5ml) by an investigational eFlow\u00ae nebuliser is equivalent to TOBI\u00ae but in a fraction of time","volume":"8 Suppl 2","author":"Denk","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60085-9","article-title":"In-vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150mg\/1.5ml) administered by the eFlow\u00ae electronic nebuliser compared to TOBI\u00ae in the PARI LC PLUS\u00ae","volume":"9 Suppl 1","author":"Keller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0094|cit94","first-page":"322","article-title":"Tobramycin and hyaluronic acid nasal solution: beyond antimicrobial effect","volume":"46 Suppl 34","author":"Claut","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jcf.2014.02.006","article-title":"Efficacy and tolerability of a new nasal spray formulation containing hyaluronate and tobramycin in cystic fibrosis patients with bacterial rhinosinusitis","volume":"13","author":"Di Cicco","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0096|cit96","unstructured":"Pilot study to evaluate the local tolerability and efficacy of a new tobramycin 3% nasal spray formulation to reduce the bacterial density of Pseudomonas aeruginosa and\/or Staphylococcus aureus, in patients affected by Cystic Fibrosis with rhinosinusal infection - ND trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-003628-39-IT"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jcf.2016.01.005","article-title":"Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026)treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"15","author":"Elborn","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(14)60050-3","article-title":"Prolonged improvement in lung function and quality of life in cystic fibrosis: a 24-week extension study of levofloxacin nebulization solution (APT-1026) versus tobramycin nebulization solution in stable CF patients with chronic pseudomonas aeruginosa infection","volume":"13 Suppl 2","author":"Elborn","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S1569-1993(13)60108-3","article-title":"Phase 3 trial of inhaled levofloxacin (Aeruquin\u00e2\u2122, MP-376, APT-1026) vs. tobramycin inhalation solution (TIS) in intensively treated CF patients over 6 months","volume":"12 Suppl 1","author":"Elborn","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jcf.2014.12.013","article-title":"A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients","volume":"14","author":"Elborn","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jcf.2014.12.013","article-title":"A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients","volume":"14","author":"Elborn","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S1569-1993(16)30277-6","article-title":"Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection","volume":"15 Suppl 1","author":"Van Devanter","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0103|cit103","first-page":"359","article-title":"Pulmonary exacerbations and changes in lung function in CF adults with P. aeruginosa treated with inhaled levofloxacin (Quinsair\u00ae) or tobramycin","volume":"51 Suppl 45","author":"Fischer","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1569-1993(16)30278-8","article-title":"History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin","volume":"2015 Suppl 1","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0106|cit106","unstructured":"Flume P Trial of aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients clinicaltrials.gov\/ct2\/show\/NCT01270347"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S1569-1993(18)30377-1","article-title":"Potential taste disturbance is largely mild and diminishes with continuing treatment in cystic fibrosis patients treated with levofloxacin inhaled solution","volume":"17 Suppl 3","author":"Schwarz","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0108|cit108","first-page":"356","article-title":"How often is pulmonary exacerbation defined by \u22654 Fuchs criteria associated with antibiotic treatment?","volume":"49 Suppl 38","author":"Van Devanter","year":"2014","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jcf.2016.05.001","article-title":"Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0110|cit110","first-page":"352","article-title":"Aztreonam for inhalation solution (AZLI) and tobramycin inhalation solution (TIS) continuous alternating therapy (CAT) for cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection: a randomized, double-blind, placebo-controlled trial","volume":"50 Suppl 41","author":"Flume","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0112|cit112","unstructured":"Flume P MP-376 (Aeroquin\u2122, Levofloxacin for Inhalation) in patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01180634"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0115|cit115","first-page":"356","article-title":"How often is pulmonary exacerbation defined by \u22654 Fuchs criteria associated with antibiotic treatment?","volume":"49 Suppl 38","author":"Van Devanter","year":"2014","journal-title":"Pediatric Pulmonlogy"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonisation with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"Frederiksen","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0117|cit117","first-page":"A13","article-title":"Inhaled aztreonam lysine recovers lung function and improves quality of life in acute pulmonary exacerbations of cystic fibrosis","volume":"74","author":"Frost","year":"2019","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0118|cit118","first-page":"430","article-title":"Aztreonam lysine inhalation solution recovers lung function and improves quality of life in treatment of acute pulmonary exacerbation of cystic fibrosis","volume":"54 Suppl 2","author":"Frost","year":"2019","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/S1569-1993(20)30485-9","article-title":"Aztreonam lysine recovers lung function and improves quality of life in the treatment of acute exacerbations of cystic fibrosis: results from an open-label randomised crossover study (AZTEC-CF)","volume":"19 Suppl","author":"Frost","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1569-1993(20)30422-7","article-title":"Inhaled and intravenous treatment strategies exert different effects on the lung microbiome during acute pulmonary exacerbations of cystic fibrosis: results from the AZTEC-CF study","volume":"19 Suppl","author":"Frost","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD004197.pub6-BIB0121|cit121","first-page":"330","article-title":"Aztec-CF study: aztreonam lysine for inhalation in the treatment of pulmonary exacerbations of cystic fibrosis","volume":"53","author":"Frost","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jcf.2020.12.012","article-title":"The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: an open-label randomised crossover study (AZTEC-CF)","volume":"20","author":"Frost","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0123|cit123","unstructured":"Aztreonam for inhalation solution (AZLI) for the treatment of exacerbations of cystic fibrosis clinicaltrials.gov\/show\/NCT02894684"},{"issue":"Suppl 27","key":"10.1002\/14651858.CD004197.pub6-BIB0124|cit124","first-page":"250","article-title":"A phase 1 study to assess the tolerability of a novel tobramycin powder for inhalation (TPI) formulation in cystic fibrosis subjects","volume":"38","author":"Geller","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0126|cit126","first-page":"250","article-title":"Single dose pharmacokinetics of tobramycin after administration of a novel dry powder formulation (TPI) in subjects with cystic fibrosis (cf)","volume":"38 Suppl 27","author":"Rodriguez","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD004197.pub6-BIB0127|cit127","first-page":"A2239","article-title":"Phase 2b study of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients with chronic Pseudomonas Aeruginosa (PA) lung infection","volume":"181","author":"Conrad","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(10)60087-2","article-title":"Effects of inhaled MP-376 (aeroquin, levofloxacin inhalation solution) on lung function in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection","volume":"9 Suppl 1","author":"Flume","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(11)60105-7","article-title":"Effects of inhaled MP-376 (Aeroquin\u00e2\u201e\u00a2 levofloxacin inhalation solution) on cystic fibrosis patients with both Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) lung infection","volume":"10 Suppl 1","author":"Flume","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD004197.pub6-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004197.pub6-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0133|cit133","first-page":"301","article-title":"Effects of inhaled MP-376 (aeroquin, levofloxacin inhalation solution) on the need for other anti-pseudomonal antimicrobials in stable CF patients with chronic pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Geller","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD004197.pub6-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ppul.20625","article-title":"Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis","volume":"42","author":"Gibson","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0137|cit137","first-page":"299","article-title":"Full analysis of data from two phase II blinded & placebo-controlled studies of nebulized liposomal amikacin for inhalation (Arikace) in the treatment of CF patients with Pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Clancy","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD004197.pub6-BIB0138|cit138","first-page":"A1836","article-title":"Evaluation of two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin (arikace\") in the treatment of cystic fibrosis patients with pseudomonas aeruginosa lung infection","volume":"181","author":"Dupont","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub6-BIB0139|cit139","first-page":"295","article-title":"A phase 2 blinded and placebo-controlled study of nebulized liposomal amikacin (arikace) in the treatment of CF patients with Pseudomonas aeruginosa lung infection","volume":"44","author":"Goss","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0140|cit140","unstructured":"Safety\/tolerability study of arikayce\u2122 in cystic fibrosis patients with chronic infection due to pseudomonas aeruginosa clinicaltrials.gov\/show\/NCT00558844"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0141|cit141","first-page":"79","article-title":"Eradication of initial Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"7","author":"Griese","year":"2002","journal-title":"European Journal of Medical Research"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0142|cit142","unstructured":"Scandinavian Cystic Fibrosis Azithromycin Study Supplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin Study trialsearch.who.int\/?TrialID=EUCTR2006-003275-12-DK"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0143|cit143","first-page":"318","article-title":"Azithromycin in combination with inhaled colimycin and oral ciprofloxacin used for intermittent pseudomonas aeruginosa colonization in cystic fibrosis patients: results from a Scandinavian study","volume":"50 Suppl 41","author":"Hansen","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0144|cit144","unstructured":"Scandinavian cystic fibrosis azithromycin study https:\/\/clinicaltrials.gov\/show\/NCT00411736"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ppul.10019","article-title":"Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study","volume":"33","author":"Heinzl","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1569-1993(17)30338-7","article-title":"Combined dry powder tobramycin and nebulized colistin versus colistin inhalation in CF patients - a randomised, open label phase III clinical study","volume":"16 Suppl 1","author":"Herrmann","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(09)60158-2","article-title":"Eradication of Pseudomonas aeruginosa in adults with CF","volume":"8 Suppl 2","author":"Kenny","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"e000021","DOI":"10.1136\/bmjresp-2014-000021","article-title":"Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis","volume":"1","author":"Kenny","year":"2014","journal-title":"BMJ Open Respiratory Research"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0149|cit149","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A1186","article-title":"Tobramycin inhalation powder is effective and safe in the treatment of chronic pulmonary Pseudomonas aeruginosa (Pa) infection in patients with cystic fibrosis","volume":"179","author":"Konstan","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(09)60109-0","article-title":"Effective treatment of chronic Pseudomonas aeruginosa (Pa) infection with tobramycin inhalation powder in CF patients","volume":"8 Suppl 2","author":"Konstan","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.21356","article-title":"Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial","volume":"46","author":"Konstan","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0152|cit152","first-page":"344","article-title":"Safety of inhaled tobramycin in patients with cystic fibrosis","volume":"46 Suppl 34","author":"McColley","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0153|cit153","unstructured":"Tobramycin inhalation powder (TIP) in cystic fibrosis subjects (EVOLVE) clinicaltrials.gov\/ct2\/show\/NCT00125346"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1569-1993(14)60179-X","article-title":"Tobramycin powder for inhalation is effective in advanced stage CF lung disease: the EAGER trial","volume":"13 Suppl 2","author":"Chiron","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0155|cit155","unstructured":"A randomized, open-label, multicenter, phase 3 trial to assess the safety of tobramycin inhalation powder compared to TOBI\u00ae in cystic fibrosis subjects trialsearch.who.int\/?TrialID=EUCTR2005-003772-37-DE"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60084-7","article-title":"Treatment convenience and satisfaction of tobramycin inhalation powder (TIP) versus TOBI in cystic fibrosis (CF) patients","volume":"9 Suppl 1","author":"Geller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(11)60100-8","article-title":"Microbiological and clinical response to tobramycin inhalation powder (TIP\u00e2\u201e\u00a2) in cystic fibrosis patients with chronic Pseudomonas aeruginosa (Pa) infection [abstract]","volume":"10 Suppl 1","author":"Geller","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4187\/respcare.02264","article-title":"Tobramycin inhalation powder in cystic fibrosis patients: response by age group","volume":"59","author":"Geller","year":"2014","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60083-5","article-title":"Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa (Pa)","volume":"9 Suppl 1","author":"Konstan","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0160|cit160","first-page":"303","article-title":"Tobramycin inhalation powder (TIP) versus tobramycin inhalation solution (TOBI\u00ae): the EAGER trial","volume":"45 Suppl 33","author":"Konstan","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0162|cit162","first-page":"344","article-title":"Safety of inhaled tobramycin in patients with cystic fibrosis","volume":"46 Suppl 34","author":"McColley","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0163|cit163","unstructured":"Safety of tobramycin inhalation powder (TIP) vs tobramycin solution for inhalation in patients with cystic fibrosis clinicaltrials.gov\/show\/NCT00388505"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0164|cit164","first-page":"283","article-title":"Reduced administration time for inhaled tobramycin in cystic fibrosis patients: results from the EAGER trial","volume":"48 Suppl 36","author":"Nasr","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(11)60345-7","article-title":"Validation of the treatment satisfaction questionnaire for medication (TSQM) in cystic fibrosis","volume":"10 Suppl 1","author":"Regnault","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S1569-1993(11)60336-6","article-title":"Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study","volume":"10 Suppl 1","author":"Regnault","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jcf.2012.04.007","article-title":"Validation of the treatment satisfaction questionnaire for medication in patients with cystic fibrosis","volume":"11","author":"Regnault","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0168|cit168","first-page":"317","article-title":"Analysis of long-term liposomal amikacin for inhalation in patients with cystic fibrosis and chronic infection from pseudomonas aeruginosa","volume":"49 Suppl 38","author":"Bilton","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(15)30289-7","article-title":"Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) who have chronic infection from Pseudomonas aeruginosa","volume":"14 Suppl 1","author":"Bilton","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0170|cit170","first-page":"270","article-title":"Long-term study of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) and chronic pseudomonas aeruginosa infection","volume":"50 Suppl 41","author":"Konstan","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jcf.2007.07.001","article-title":"Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis","volume":"7","author":"Latzin","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00148581-200709001-00003","article-title":"Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"9 Suppl","author":"Lenoir","year":"2007","journal-title":"Paediatric Drugs"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1569-1993(06)80166-9","article-title":"Aerosolized tobramycin in the treatment of patients with cystic fibrosis and pseudomonas aeruginosa infection","volume":"5 Suppl 1","author":"Lenoir","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0174|cit174","first-page":"620s","article-title":"Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"26 Suppl 49","author":"Lenoir","year":"2005","journal-title":"European Respiratory Journal"},{"issue":"8433","key":"10.1002\/14651858.CD004197.pub6-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(85)92222-6","article-title":"Nebulised colomycin for early pseudomonal colonisation in cystic fibrosis","volume":"1","author":"Littlewood","year":"1985","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0176|cit176","unstructured":"Nasale inhalation von tobramycin mit dem pari sinus-vernebler bei patienten mit mukoviszidose und pseudomonasnachweis IM nasen-nasennebenhohlenbereich. Nasal inhalation of tobramycin by the pari sinus nebulizer in patients with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways. - tobra nasal CF pilot trialsearch.who.int\/?TrialID=EUCTR2008-000164-17-DE"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/DDDT.S54064","article-title":"Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study","volume":"8","author":"Mainz","year":"2014","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(11)60101-X","article-title":"Sinonasal inhalation of tobramycin in cystic fibrosis patients with P. aeruginosa colonization of the upper airways - results of a multicentric placebo-controlled pilot study","volume":"10 Suppl 1","author":"Mainz","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anl.2010.09.001","article-title":"Sinonasal inhalation of dornase alfa in CF: a double-blind placebo-controlled cross-over pilot trial","volume":"38","author":"Mainz","year":"2011","journal-title":"Auris, Nasus, Larynx"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0180|cit180","unstructured":"Nasal inhalation of tobramycin in patients with cystic fibrosis and pseudomonas aeruginosa colonization clinicaltrials.gov\/show\/NCT00774072"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0181|cit181","first-page":"S28","article-title":"Comparison of two inhaled tobramycin solutions in cystic fibrosis patients with chronic pseudomonas aeruginosa infection: results in different age subgroups","volume":"10 Suppl 1","author":"Mazurek","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S1569-1993(12)60239-2","article-title":"Efficacy on lung function and safety of multiple courses of tobramycin 300mg\/4 ml nebuliser solution (Bramitob) in patients with cystic fibrosis and chronic pseudomonas aeruginosa infection: results from a 48-week extension phase","volume":"11 Suppl1","author":"Mazurek","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0183|cit183","first-page":"S28","article-title":"Head-to-head comparison of two inhaled tobramycin solutions in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (Pa) infection","volume":"10 Suppl 1","author":"Mazurek","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub6-BIB0184|cit184","first-page":"309","article-title":"Antibiotic susceptibility in Pseudomonas Aeruginosa (PA) isolates following exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis","volume":"44","author":"Oermann","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 32","key":"10.1002\/14651858.CD004197.pub6-BIB0185|cit185","first-page":"335","article-title":"Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens","volume":"44","author":"Oermann","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0186|cit186","first-page":"S28","article-title":"Effect of multiple courses of Aztreonam Lysine for inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): analysis of 18 month data from CP-AI-006","volume":"8 Suppl 2","author":"Oermann","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0187|cit187","first-page":"S28","article-title":"Adherence over multiple courses of Aztreonam for inhalation (AZLI): effect on disease- related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA)","volume":"8 Suppl 2","author":"Oermann","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD004197.pub6-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0189|cit189","first-page":"299","article-title":"Effects of chronic intermittent aztreonam for inhalation solution (AZLI) on health-related quality of life (HRQOL) in persons with cystic fibrosis (CF) and P. aeruginosa","volume":"46 Suppl 34","author":"Quitnner","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"8","key":"10.1002\/14651858.CD004197.pub6-BIB0190|cit190","first-page":"25","article-title":"Evaluation of pefloxacin efficacy and tolerability in the treatment and prophylaxis of severe infections at the children with mucoviscidosis and aplastic anaemia","volume":"45","author":"Postnikov","year":"2000","journal-title":"Antibiotiki i Khimioterapiia"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S1569-1993(07)60126-X","article-title":"A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients","volume":"6 Suppl 1","author":"Postnikov","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0192|cit192","unstructured":"Circadian rhythm in tobramycin elimination in cystic fibrosis clinicaltrials.gov\/show\/NCT01207245"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0193|cit193","first-page":"299","article-title":"Are morning doses of intravenous tobramycin less nephrotoxic than evening? Evidence from urinary biomarkers in the critic study","volume":"48 Suppl 36","author":"Prayle","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jcf.2015.07.012","article-title":"The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: a randomised comparison","volume":"15","author":"Prayle","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0195|cit195","first-page":"273","article-title":"Economic analysis of hospitalization and home IV anti-pseudomonal antibiotic use in CF patients on tobramycin solution for inhalation (TOBI\u00ae)","volume":"Suppl 17","author":"Birnbaum","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/S1569-1993(02)00003-6","article-title":"The long-term use of inhaled tobramycin in patients with cystic fibrosis","volume":"1 Suppl 2","author":"Bowman","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis","volume":"179","author":"Burns","year":"1999","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0198|cit198","unstructured":"Casey S Ramsey B Borowitz D Nutritional benefits of chronic intermittent Pseudomonas aeruginosa suppression with tobramycin solution for inhalation in adolescents 13th International Cystic Fibrosis Congress; 2000 Jun 4-8; Stockholm, Sweden 2000 172"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0199|cit199","first-page":"339","article-title":"Mortality rates during 2 years of treatment with intermittent inhaled tobramycin (TOBI) in CF","volume":"Suppl 19","author":"Enger","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD004197.pub6-BIB0200|cit200","first-page":"1545","article-title":"Long term effect of tobramycin solution for inhalation on reduction of hospitalization of CF patients [abstract]","volume":"16","author":"Fiel","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD004197.pub6-BIB0201|cit201","first-page":"1545","article-title":"Long term effect of tobramycin solution for inhalation on reduction of hospitalization of CF patients","volume":"16","author":"Fiel","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0203|cit203","first-page":"283","article-title":"Epidemiology of Stenotrophomonas maltophilia culture in cystic fibrosis (CF) patients during the tobramycin solution for inhalation (TOBI\u00ae) study","volume":"Suppl 20","author":"Graff","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0204|cit204","first-page":"130","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"135","author":"Hazinski","year":"1999","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0205|cit205","first-page":"305","article-title":"Peripheral white blood cell count as a surrogate marker for progression of lung disease in cystic fibrosis","volume":"Suppl 22","author":"Konstan","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl","key":"10.1002\/14651858.CD004197.pub6-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0300-2977(99)90288-7","article-title":"Who benefits more? An age-stratified analysis of lung function and weight gain in CF patients using inhaled tobramycin","volume":"54","author":"Kylstra","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0149-2918(00)87985-0","article-title":"Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis","volume":"22","author":"LeLorier","year":"2000","journal-title":"Clinical Therapeutics"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004197.pub6-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"118S","DOI":"10.1378\/chest.120.3_suppl.118S","article-title":"Microbiological and immunologic considerations with aerosolized drug delivery","volume":"120","author":"LiPuma","year":"2001","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/315312","article-title":"Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment","volume":"181","author":"MacLeod","year":"2000","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0210|cit210","first-page":"243","article-title":"Who benefits more? An analysis of FEV1 and weight in adolescent (age 13-<18) CF patients using inhaled tobramycin (TOBI)","volume":"Suppl 19","author":"Moss","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004197.pub6-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"107S","DOI":"10.1378\/chest.120.3_suppl.107S","article-title":"Administration of aerosolized antibiotics in cystic fibrosis patients","volume":"120","author":"Moss","year":"2001","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0213|cit213","unstructured":"A study of the safety and efficacy of tobramycin for inhalation in young children with cystic fibrosis clinicaltrials.gov\/show\/NCT00006280"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0214|cit214","first-page":"243","article-title":"Safety and effectiveness of 2 years of treatment with intermittent inhaled tobramycin in CF patients","volume":"Suppl 19","author":"Nickerson","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0215|cit215","first-page":"273","article-title":"Seasonality of hospitalization for pulmonary exacerbations and lower respiratory tract infections in Phase III tobramycin solution for inhalation (TOBI\u00ae) trials","volume":"Suppl 17","author":"Otto","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl","key":"10.1002\/14651858.CD004197.pub6-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S0300-2977(99)90290-5","article-title":"Treatment for exacerbation only does not arrest progressive lung function decline in CF","volume":"54","author":"Quan","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0217|cit217","unstructured":"Quittner A Gordon D Yu X Convergence of quality of life assessments and clinical outcomes in patients enrolled in the tobramycin solution for inhalation (TSI) trials 24th European Cystic Fibrosis Conference; 2001 Jun 6-9; Vienna, Austria 2001 P326"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0218|cit218","first-page":"349","article-title":"Longitudinal changes in global ratings of quality of life for patients in the tobramycin solution for inhalation (TSI) trials","volume":"Suppl 22","author":"Quittner","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ppul.10074","article-title":"Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"33","author":"Quittner","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0220|cit220","first-page":"137","article-title":"Safety and efficacy of Tobramycin Solution for Inhalation in patients with cystic fibrosis: the results of two phase III placebo controlled clinical trials","volume":"Suppl 14","author":"Ramsey","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0221|cit221","unstructured":"Ramsey BW Bowman MC Montgomery AB Smith AR TOBIStudy G Design of phase 3 aerosolized tobramycin studies for chronic intermittent therapy 21st European Cystic Fibrosis Conference; 1997 Jun 1-6; Davos, Switzerland 1997 144"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0222|cit222","unstructured":"Ramsey BW Bowman MC Smith AR TOBIStudy G Results of phase 3 aerosolized tobramycin studies for chronic intermittent therapy 21st European Cystic Fibrosis Conference; 1997 Jun 1-6; Davos, Switzerland 1997 144"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1067\/mpd.2001.117288","article-title":"Defining a pulmonary exacerbation in cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0225|cit225","first-page":"291","article-title":"Nebulised high dose Tobramycin (TOBI) in adolescents with cystic fibrosis","volume":"Suppl 22","author":"Taylor","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0226|cit226","first-page":"298","article-title":"Effect of tobramycin solution for inhalation (TOBI\u00ae) on long term rates of lung function decline in Pseudomonas aeruginosa infected cystic fibrosis (CF) patients with mild to moderate lung disease","volume":"Suppl 20","author":"VanDevanter","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0227|cit227","unstructured":"VanDevanter D Yu X Konstan MW Effect of tobramycin solution for inhalation on circulating white blood cell counts in exacerbating and stable CF patients 24th European Cystic Fibrosis Conference; 2001 Jun 6-9; Vienna, Austria 2001 P172"},{"issue":"9286","key":"10.1002\/14651858.CD004197.pub6-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(01)06124-4","article-title":"Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"358","author":"Ratjen","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0229|cit229","first-page":"S55","article-title":"Microbiology results from a phase 2 clinical study of aztreonam lysinate for inhalation (AI): a new inhaled antibiotic to treat CF patients with Pseudomonas aeruginosa (PA)","volume":"4 Suppl","author":"Burns","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ppul.20736","article-title":"A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"43","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0231|cit231","unstructured":"Retsch-Bogart GZ Gibson RL A phase 2 study of aztreonam lysinate for inhalation to treat cystic fibrosis patients with Pseudomonas aeruginosa infection American Thoracic Society International Conference; 2005 May 20-25; San Diego, USA 2005 A576"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0232|cit232","first-page":"320","article-title":"Sustained improvement in pulmonary function following a 28-day course of 75mg azli tid therapy","volume":"43 Suppl 31","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0233|cit233","first-page":"341","article-title":"Investigation of susceptibility breakpoints for inhaled antibiotic therapies in cystic fibrosis","volume":"45 Suppl 33","author":"McCoy","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1569-1993(09)60112-0","article-title":"Efficacy of Aztreonam Lysine for inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA)","volume":"8 Suppl 2","author":"McCoy","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0235|cit235","first-page":"351","article-title":"Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis","volume":"43 Suppl 31","author":"McCoy","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"14","key":"10.1002\/14651858.CD004197.pub6-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2165\/10484070-000000000-00000","article-title":"Aztreonam lysine for inhalation solution: in cystic fibrosis","volume":"70","author":"Plosker","year":"2010","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0237|cit237","first-page":"299","article-title":"Effects of chronic intermittent aztreonam for inhalation solution (AZLI) on health-related quality of life (HRQOL) in persons with cystic fibrosis (CF) and P. aeruginosa","volume":"46 Suppl 34","author":"Quittner","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0238|cit238","first-page":"305","article-title":"Effect of a 28-day course of aztreonam for inhalation solution (AZLI) on responses to individual CFQ-R respiratory symptoms score questions among patients with CF","volume":"44 Suppl 32","author":"Quittner","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0239|cit239","first-page":"320","article-title":"Source of improvements in lung function in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation (AZLI)","volume":"43 Suppl 31","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0240|cit240","first-page":"320","article-title":"Sustained improvement in pulmonary function following a 28-day course of 75mg azli tid therapy","volume":"43 Suppl 31","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0241|cit241","first-page":"310","article-title":"Phase 3 trial (AIR-CF 1) measuring improvement in respiratory symptoms in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation","volume":"42 Suppl 30","author":"Retsch-Bogart","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(09)60110-7","article-title":"Pharmacokinetics of tobramycin (TOBI) after 4 and 8 weeks of continuous once daily or twice daily inhalation","volume":"8 Suppl 2","author":"Rietschel","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0244|cit244","first-page":"320","article-title":"Pharmacokinetics of continuous treatment with O.D. or B.I.D inhalation of tobramycin (TOBI\u2122) via Pari Eflow\u2122 Rapid","volume":"45 Suppl 33","author":"Rietschel","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(10)60086-0","article-title":"Pharmacokinetics of continuous treatment with o.d. or b.i.d. inhalation of tobramycin (TOBITM)","volume":"9 Suppl 1","author":"Rietschel","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/jac\/dkv399","article-title":"Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients","volume":"71","author":"Van Koningsbruggen-Rietschel","year":"2016","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/jamp.2011.0942","article-title":"Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin","volume":"26","author":"Ruddy","year":"2013","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00006454-199701000-00032","article-title":"Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis","volume":"16","author":"Schaad","year":"1997","journal-title":"Pediatric Infectious Diseases Journal"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(09)60156-9","article-title":"Genotype based evaluation of eradication treatment of new P. aeruginosa infections in CF patients","volume":"8 Suppl 2","author":"Schelstraete","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jcf.2009.11.006","article-title":"Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients","volume":"9","author":"Schelstraete","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0251|cit251","unstructured":"A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOBI\u00ae) in cystic fibrosis patients with pseudomonas aeruginosa lung infection trialsearch.who.int\/?TrialID=EUCTR2004-003675-36-BE"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1569-1993(12)60038-1","article-title":"A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe\u00ae) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection","volume":"11 Suppl 1","author":"Goldman","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0253|cit253","first-page":"331","article-title":"Lack of emergence of antimicrobial resistance of Pseudomonas Aeruginosa after six months inhalation of dry powder colistimethate","volume":"43 Suppl 31","author":"Goldman","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"S35","key":"10.1002\/14651858.CD004197.pub6-BIB0254|cit254","first-page":"353","article-title":"A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of colistimethate sodium (Colobreathe\u00ae) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection","volume":"47","author":"Goldman","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0255|cit255","first-page":"347","article-title":"Does persistence with inhaled dry powder antibiotic treatment improve tolerability?","volume":"48 Suppl 36","author":"Goldman","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30295-2","article-title":"Efficacy and safety of colistimethate sodium in a paediatric population: results from the FREEDOM trial","volume":"14 Suppl 1","author":"Schuster","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jamp.2013.1056","article-title":"Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a Phase I, randomized, single-dose, dose-escalation study","volume":"28","author":"Stass","year":"2015","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0260|cit260","first-page":"300","article-title":"Safety and pharmacokinetics of inhaled dry powder ciprofloxacin after single and multiple inhalations in patients with cystic fibrosis","volume":"43 Suppl 31","author":"Stass","year":"2008","journal-title":"Paediatric Pulmomology"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub6-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","article-title":"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study","volume":"35","author":"Stass","year":"2013","journal-title":"Clinical Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD004197.pub6-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/adc.64.7.1022","article-title":"Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis","volume":"64","author":"Steinkamp","year":"1989","journal-title":"Archives of Disease in Childhood"},{"issue":"S30","key":"10.1002\/14651858.CD004197.pub6-BIB0263|cit263","first-page":"300","article-title":"Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic Pseudomonas aeruginosa infection","volume":"42","author":"Steinkamp","year":"2007","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(06)80098-6","article-title":"Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa","volume":"5 Suppl 1","author":"Steinkamp","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0265|cit265","first-page":"315","article-title":"A phase 1 safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients","volume":"43 Suppl 31","author":"Geller","year":"2008","journal-title":"Paediatric Pulmonology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004197.pub6-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60101-0","article-title":"Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications","volume":"7","author":"Griffith","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(11)60106-9","article-title":"Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis","volume":"10 Suppl 1","author":"Kearns","year":"2011","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17476348.2015.986469","article-title":"Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis","volume":"9","author":"Stockmann","year":"2015","journal-title":"Expert Review of Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1183\/09031936.05.00009605","article-title":"Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients","volume":"26","author":"Taccetti","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S1569-1993(09)60148-X","article-title":"Prevention of initial P. aeruginosa infection in children with cystic fibrosis: a multi-centre double-blind randomised controlled trial","volume":"8 Suppl 2","author":"Tramper-Stranders","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub6-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/thx.2009.126128","article-title":"Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"65","author":"Tramper-Stranders","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0272|cit272","first-page":"338","article-title":"Fosfomycin\/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and pseudomonas aeruginosa","volume":"45 Suppl 33","author":"McColley","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0273|cit273","first-page":"302","article-title":"Fosfomycin\/tobramycin for inhalation FTI): safety results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and pseudomonas aeruginosa","volume":"45 Suppl 33","author":"Trapnell","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0275|cit275","first-page":"302","article-title":"Fosfomycon\/tobramycin for inhalation (FTI): efficacy results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and pseudomonas aeruginosa","volume":"45 Suppl 33","author":"Trapnell","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1651-2227.1993.tb12668.x","article-title":"Early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis","volume":"82","author":"Vazquez","year":"1993","journal-title":"Acta Paediatrica Scandanavia"},{"issue":"7","key":"10.1002\/14651858.CD004197.pub6-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thoraxjnl-2012-202342","article-title":"Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age","volume":"68","author":"Byrnes","year":"2013","journal-title":"Thorax"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004197.pub6-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(09)60157-0","article-title":"Interim outcomes of a Pseudomonas aeruginosa (Pa) eradication protocol in young children in the Australian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study","volume":"8","author":"Cheney","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S1569-1993(10)60452-3","article-title":"Trials, tribulations and triumphs of a cystic fibrosis study - a behind the scenes look at the workings of an international multi-centre study","volume":"9 Suppl 1","author":"Cheney","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcf.2014.12.007","article-title":"Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years","volume":"14","author":"Kidd","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jpeds.2014.05.031","article-title":"Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosis","volume":"165","author":"Moodie","year":"2014","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0282|cit282","first-page":"317","article-title":"Australasian cystic fibrosis BAL study interim analysis","volume":"41 Suppl 29","author":"Wainwright","year":"2006","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub6-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ppul.20885","article-title":"Safety of bronchoalveolar lavage in young children with cystic fibrosis","volume":"43","author":"Wainwright","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0284|cit284","first-page":"300","article-title":"Early infection with pseudomonas aeruginosa can be cleared in young children with cystic fibrosis","volume":"34 Suppl 24","author":"Wainwright","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0285|cit285","first-page":"320","article-title":"Australasian CF bronchoalveolar lavage (ACFBAL) study: P.Aeruginosa (PA) genotypes in pre-school CF children","volume":"46 Suppl 34","author":"Wainwright","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2011.954","article-title":"Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2011.954","article-title":"Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60082-3","article-title":"A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa","volume":"9 Suppl 1","author":"Wainwright","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2011.02.007","article-title":"Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa","volume":"10","author":"Wainwright","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0290|cit290","unstructured":"Comparison of antibiotics for pseudomonas in early CF clinicaltrials.gov\/show\/NCT00823238"},{"issue":"S30","key":"10.1002\/14651858.CD004197.pub6-BIB0291|cit291","first-page":"332","article-title":"Comparison of antibiotics for early pseudomonas infection in CF: interim data analysis","volume":"42","author":"Noah","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ppul.21176","article-title":"Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas","volume":"45","author":"Noah","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0293|cit293","unstructured":"Assesment of efficacy and tolerability of inhaled tobramycin vs placebo in cystic fibrosis patients receiving antibiotherapy for 28 days for pseudomonas aeruginosa primo colonisation. - nebcinal 01-07 trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-003868-22-FR"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0294|cit294","unstructured":"Multicentric and randomized study to evaluate the effectiveness of the association of the 2 different treatments in the early P.aerugionsa infection in patient with cystic fibrosis disease. The study will enlist pazients over 5 years old trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2011-006171-19-IT"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0295|cit295","unstructured":"Clinical study to assess two different Pseudomonas aeruginosa eradication protocols in patients with cystic \u00bfbrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-003881-96-IT"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3476(05)80729-2","article-title":"Early bacteriologic, immunologic and clinical courses of young infants with cystic fibrosis identified by neonatal screening","volume":"119","author":"Abman","year":"1991","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcf.2012.08.001","article-title":"Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial","volume":"12","author":"Anstead","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K","article-title":"Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis","volume":"21","author":"Armstrong","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0299|cit299","doi-asserted-by":"publisher","first-page":"2000512","DOI":"10.1183\/13993003.00512-2020","article-title":"Omics-based tracking of Pseudomonas aeruginosa persistence in \"eradicated\" cystic fibrosis patients","volume":"57","author":"Bartell","year":"2021","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1086\/318075","article-title":"Longitudanal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis","volume":"183","author":"Burns","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1574-695X.2012.00983.x","article-title":"Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections","volume":"65","author":"Ciofu","year":"2012","journal-title":"FEMS Immunology and Medical Microbiology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0302|cit302","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook."},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1183\/09031936.00043108","article-title":"Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis","volume":"33","author":"Douglas","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa: a European consensus","volume":"16","author":"D\u00f6ring","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"D\u00f6ring","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"12","key":"10.1002\/14651858.CD004197.pub6-BIB0307|cit307","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41431-018-0234-z","article-title":"Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis","volume":"26","author":"Farrell","year":"2018","journal-title":"European Journal of Human Genetics"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3476(05)83478-X","article-title":"The changing epidemiology of cystic fibrosis","volume":"122","author":"FitzSimmons","year":"1993","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0309|cit309","first-page":"267","article-title":"The Cystic Fibrosis Foundation patient registry report 1996","volume":"Suppl 21","author":"Fitzsimmons","year":"1996","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0310|cit310","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub6-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/adc.2006.105825","article-title":"Bronchoscopy following diagnosis with cystic fibrosis","volume":"92","author":"Hilliard","year":"2007","journal-title":"Archives of Disease in Childhood"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3476(09)90007-5","article-title":"Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years","volume":"122","author":"Hudson","year":"1993","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0313|cit313","first-page":"115","article-title":"Respiratory Tract Bacteriology in Cystic Fibrosis","volume":"106","author":"Iacocca","year":"1963","journal-title":"American Journal of Disease in Childhood"},{"issue":"8","key":"10.1002\/14651858.CD004197.pub6-BIB0314|cit314","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001399.pub4","article-title":"Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis","author":"Johansen","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD004197.pub6-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00006454-199007000-00008","article-title":"Risk factors for Pseudomonas aeruginosa colonisation in cystic fibrosis patients","volume":"9","author":"Kerem","year":"1990","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ppul.10401","article-title":"Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center","volume":"37","author":"Lee","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1479972309104661","article-title":"Eradication of early Pseudomonas infection in cystic fibrosis","volume":"6","author":"Lee","year":"2009","journal-title":"Chronic Respiratory Disease"},{"issue":"17","key":"10.1002\/14651858.CD004197.pub6-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit: a systematic review","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1164\/ajrccm.160.1.9808096","article-title":"Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients","volume":"160","author":"Muhlebach","year":"1999","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ppul.1121","article-title":"Genotypic characterisation of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonisation","volume":"32","author":"Munck","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1067\/mpd.2001.112897","article-title":"Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis","volume":"138","author":"Nixon","year":"2001","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ppul.1950190103","article-title":"Effects of Pseudomonas aeruginosa colonisation on lung function and anthropomorphic variables in children with cystic fibrosis","volume":"19","author":"Pamukcu","year":"1995","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1128\/IAI.67.9.4744-4750.1999","article-title":"Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype","volume":"67","author":"Parad","year":"1999","journal-title":"Infection & Immunity"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub6-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/1099-0496(200101)31:1<13::AID-PPUL1001>3.0.CO;2-N","article-title":"Effect of continuous antistaphylococcal therapy on the rate of P.aeruginosa acquisition in patients with cystic fibrosis","volume":"31","author":"Ratjen","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V","article-title":"Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis","volume":"28","author":"Rosenfeld","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ppul.1144","article-title":"Early pulmonary infection, inflammation and clinical outcomes in infants with cystic fibrosis","volume":"32","author":"Rosenfeld","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub6-BIB0330|cit330","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001912.pub5","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","author":"Rosenfeld","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub6-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in randomised controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004197.pub6-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jcf.2014.03.010","article-title":"European Cystic Fibrosis Society Standards of Care: Best Practice Guidelines","volume":"13","author":"Smyth","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1067\/mpd.2002.121930","article-title":"Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomised controlled trial","volume":"140","author":"Stutman","year":"2002","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub6-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0022-3476(84)81094-X","article-title":"Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis","volume":"104","author":"Thomassen","year":"1984","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0335|cit335","volume-title":"Cystic Fibrosis Trust Patient Registry User\u2019s Guide","year":"2012"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0336|cit336","unstructured":"UK CF Trust Control of Infection Group Pseudomonas aeruginosa infection in people with cystic fibrosis: suggestions for prevention and control (2nd edition) UK CF Trust 2004"},{"key":"10.1002\/14651858.CD004197.pub6-BIB0337|cit337","unstructured":"UK Cystic Fibrosis 2020 Registry Annual data Report cysticfibrosis.org.uk\/registryreports"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ppul.1950100210","article-title":"Respiratory tract colonisation with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function","volume":"10","author":"Winnie","year":"1991","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0339|cit339","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub3","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Langton-Hewer","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD004197.pub6-BIB0340|cit340","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub4","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Langton-Hewer","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub6-BIB0341|cit341","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub5","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Langton-Hewer","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub6-BIB0342|cit342","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Wood","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub6-BIB0343|cit343","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub2","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Wood","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:18:17Z","timestamp":1752671897000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004197.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":343,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004197.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}